Clinical trials: Obese Adults
Obesity
A Safety and Efficacy Study of VI-0521 to Evaluate the Long Term Treatment of Obesity in Adults With Obesity-Related Co-Morbid Conditions. An Extension Study of Protocol OB-303 (NCT00553787)
The purpose of this study is to evaluate the long-term safety and efficacy of VI-0521 compared to placebo for the treatment of overweight and obesity in adults who have completed study OB-303 (NCT00553787) at selected study…
- Trial name
- NCT00796367
- Testing
- VI-0521
- Volunteers
- 676 people
- Sponsor
- VIVUS LLC
Obesity
A Study of Once-Daily Oral Orforglipron (LY3502970) in Japanese Adult Participants With Obesity Disease
The main purpose of this study is to investigate the efficacy and safety of oral orforglipron in participants with obesity disease with obesity-related health problems.
- Trial name
- ATTAIN-J (NCT05931380)
- Testing
- Orforglipron
- Where
- 16 sites in Japan
- Volunteers
- 238 people
- Sponsor
- Eli Lilly and Company
Obesity, Obese
Safety and Efficacy of Bimagrumab and Semaglutide in Adults Who Are Overweight or Obese
A phase 2 study to assess the efficacy of bimagrumab alone or in addition to semaglutide to assess efficacy and safety in overweight or obese men and women
- Conditions
- Obesity, Obese, Overweight or Obesity
- Trial name
- NCT05616013
- Testing
- Bimagrumab, Semaglutide
- Where
- 26 sites in United States, Australia and 1 more
- Volunteers
- 507 people
- Sponsor
- Eli Lilly and Company
Overweight, Obesity
A Study to Compare Two Different Forms of PF-07081532 in Adults Who Are Overweight or Obese
The purpose of this study is to compare the amount of PF-07081532 in blood after taking two different forms of PF-07081532. This study is seeking participants who are at least 18 years of age and are overweight and/or obese.
- Trial name
- NCT05677867
- Testing
- Formulation A (PF-07081532 20 mg plus 60 mg), Formulation B (PF-07081532 80 mg)
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Pfizer
Obesity, Overweight
A Study to Evaluate the Change in Weight After 24 Weeks Treatment With LIK066 in Obese or Overweight Adults
This was a dose-finding study that evaluated the change in weight after 24 weeks treatment with 8 different doses of LIK066 compared to placebo in obese or overweight adults, followed by 24 weeks treatment with 2 doses of LIK066…
- Trial name
- NCT03100058
- Testing
- LIK066
- Where
- 83 sites in United States, Austria and 5 more
- Volunteers
- 460 people
- Sponsor
- Novartis Pharmaceuticals
Type 2 Diabetes Mellitus
Study of Multiple Oral Doses of PF-07081532 in Adult Participants With Type 2 Diabetes Mellitus
This is a Phase 1, randomized, placebo-controlled, double-blind (investigator- and participant-blinded), sponsor-open study of PF-07081532.
- Trial name
- NCT05158244
- Testing
- PF-07081532
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- Pfizer
Diabetes Mellitus Type 2
A Study to Evaluate BMS-986036 in Obese Adults With Type-2 Diabetes
The purpose of this study is to assess the potential of BMS-986036 for treatment obese adults with type-2 diabetes.
- Trial name
- NCT02097277
- Testing
- BMS-986036
- Where
- 16 sites in United States, Canada
- Volunteers
- 219 people
- Sponsor
- Bristol-Myers Squibb
Antipsychotic-induced Weight Gain (AIWG)
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Miricorilant in Obese Adult Patients With Schizophrenia While Taking Antipsychotic Medications (GRATITUDE II)
This Phase 2, double-blind, placebo-controlled, randomized study is to assess the safety, efficacy, and pharmacokinetics (PK) of miricorilant (CORT118335) in obese patients with schizophrenia treated with antipsychotic…
- Trial name
- NCT04524403
- Testing
- Miricorlilant
- Where
- 40 sites in United States
- Volunteers
- 150 people
- Sponsor
- Corcept Therapeutics
Obesity, Overweight
A Study of Orforglipron (LY3502970) in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities
This study will investigate the efficacy and safety of once daily oral orforglipron in adult participants with obesity or overweight with weight-related comorbidities.
- Conditions
- Obesity, Overweight, Overweight or Obesity
- Trial name
- ATTAIN-1 (NCT05869903)
- Testing
- Orforglipron
- Where
- 138 sites in United States, Brazil and 8 more
- Volunteers
- 3,127 people
- Sponsor
- Eli Lilly and Company
Hypertension
Safety/Efficacy of Valsartan/Hydrochlorothiazide Combination Compared to Hydrochlorothiazide in Obese Hypertensive Adults
The purpose of this study is to compare the blood pressure lowering efficacy of valsartan/hydrochlorothiazide (HCTZ) compared to hydrochlorothiazide for the treatment of obese hypertensive (mean sitting systolic blood pressure…
- Trial name
- NCT00439738
- Testing
- HCTZ + Amlodipine, Valsartan/HCTZ
- Where
- 5 sites in United States
- Volunteers
- 412 people
- Sponsor
- Novartis Pharmaceuticals
Diabetes Melliuts, Type 2
Multiple Dose Study Of PF-05231023 In Adult Subjects Who Have Poor Lipid Control With And Without Type 2 Diabetes Mellitus
This is a trial in obese subjects who have poor lipid control with and without Type 2 diabetes mellitus to study the safety, tolerability and pharmacokinetics of multiple doses of PF-05231023
- Trial name
- NCT01673178
- Testing
- 25 mg PF-05231023, 50 mg PF-05231023, 100 mg PF-05231023
- Where
- 17 sites in United States
- Volunteers
- 107 people
- Sponsor
- Pfizer
Overweight, Obesity
A Research Study to See How Well Semaglutide Helps People Who Have a Body Weight Above the Healthy Weight Range
This study will look at how the investigational dose of semaglutide works in helping people with excess body weight, to lose weight.
- Trial name
- STEP12 (NCT06041217)
- Testing
- Semaglutide
- Where
- 21 sites in China, Taiwan
- Volunteers
- 242 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Obesity
Trial to Learn About the Study Medicine (PF-07081532) and Rybelsus in People With Type 2 Diabetes and Separately PF-07081532 in People With Obesity
The purpose of this study is to find out if PF-07081532 ("the active study drug"), is safe and helps treat people with obesity without diabetes to lose weight, and people with diabetes to keep their blood sugar in good control.
- Trial name
- NCT05579977
- Testing
- PF-07081532, Rybelsus
- Where
- 90 sites in United States, Bulgaria and 6 more
- Volunteers
- 902 people
- Sponsor
- Pfizer
Healthy
A Drug-Drug Interaction Study to Examine the Impact of Itraconazole and Cyclosporine on PF-07081532 Pharmacokinetics in Overweight or Obese Adults
This is a Phase 1, open-label, fixed-sequence, 3-period study to evaluate the effect of multiple doses of itraconazole and a single dose of cyclosporine on the single-dose PK of PF-07081532 in otherwise healthy, overweight or…
- Trial name
- NCT05745701
- Testing
- PF-07081532, Cyclosporine, Itraconazole
- Where
- United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Pfizer
Type 2 Diabetes Mellitus (T2DM)
Multiple Dose Study Of PF-05231023 In Obese Adult Subjects
This is a trial in obese subjects to study the safety, tolerability, pharmacokinetics and pharmacodynamics of multiple doses of PF-05231023.
- Trial name
- NCT01923389
- Testing
- 100 mg PF-05231023
- Where
- 2 sites in United States
- Volunteers
- 4 people
- Sponsor
- Pfizer
Overweight, Obese
A Study of CT-868 in Type 1 Diabetes Mellitus
This study will evaluate the changes in glycemic control in overweight and obese adults with Type 1 Diabetes Mellitus after receiving CT-868 for 16 weeks. The effectiveness and safety of CT-868 will be compared to placebo.
- Conditions
- Overweight, Obese, Type 1 Diabetes Mellitus
- Trial name
- NCT06062069
- Testing
- CT-868, CT-868 Pen Injector
- Where
- 22 sites in United States
- Volunteers
- 111 people
- Sponsor
- Carmot Therapeutics, Inc.
Chronic Weight Management
A Multicenter, Double-blind, Randomized, Parallel-group, Pilot Study of 12-week Duration to Assess the Short-term Safety and Tolerability of Lorcaserin Plus Two Doses of Immediate-Release Phentermine-HCl Compared With Lorcaserin Alone in Overweight and Obese Adults
APD356-A001-402 is a multicenter, double-blind, randomized, parallel-group pilot study of 12-week duration in overweight and obese adults.
- Trial name
- NCT01987427
- Testing
- lorcaserin + phentermine-HCl
- Where
- 13 sites in United States
- Volunteers
- 344 people
- Sponsor
- Eisai Inc.
Overweight or Obesity
A Clinical Study to Evaluate the Efficacy, Safety, and Tolerability of TERN-601 in Adults With Overweight or Obesity
This is a Phase 2a multicenter, randomized, double-blind, placebo-controlled clinical trial studying the efficacy, safety, and tolerability of orally administered TERN-601 in adults with overweight or obesity.
- Trial name
- FALCON (NCT06854952)
- Testing
- TERN-601
- Where
- 17 sites in United States
- Volunteers
- 167 people
- Sponsor
- Terns, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Obesity
Multiple Ascending Dose Study of AMG 598 in Adults With Obesity
The main objective of this study is to assess the safety and tolerability of multiple doses of AMG 598 administered alone or in combination with liraglutide in adults with obesity.
- Trial name
- NCT03757130
- Testing
- AMG 598, Liraglutide
- Where
- 4 sites in United States
- Volunteers
- 50 people
- Sponsor
- Amgen
Type 2 Diabetes Mellitus
Study of VI-0521 Compared to Placebo in the Glycemic Management of Obese Diabetics
The purpose of this study is to evaluate the efficacy and safety of VI-0521 compared to placebo in the glycemic management of obese diabetic adults.
- Trial name
- NCT00486291
- Testing
- VI-0521
- Where
- 9 sites in United States
- Volunteers
- 210 people
- Sponsor
- VIVUS LLC